We are a clinical stage company working to reverse damage/injury in the central nervous system with First in Class, Disease Modifying therapy. Our technology is based on research out of Dr. Stephen Strittmatter’s lab at Yale University that identified why, after injury, regeneration of neurons/connections occurs in the peripheral nervous system and not in the central nervous system (CNS). The key differences come down to inhibitory factors that exist in the CNS that when removed will initiate growth. These findings were published in Science, Nature and since that time have been published in peer review journals in a variety of additional academic labs as well as with industrial partners. We have both method as well as composition of matter patients issued in key countries US, Japan, China, Europe, Canada, Mexico with expiry protections to late 2030. The company has a broad pipeline of indications CNS injury such as spinal cord injury, glaucoma, and stroke.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Chronic Spinal Cord Injury
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):